Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Mydecine Innovations Group Inc. (MYCO.CN)

Mydecine Innovations Group Inc. (MYCO.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 76,499
  • Shares Outstanding, K 162,763
  • Annual Sales, $ 126 K
  • Annual Income, $ -3,508 K
  • 60-Month Beta 3.88
  • Price/Sales 1,112.09
  • Price/Cash Flow N/A
  • Price/Book 7.68
Trade MYCO.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.11
  • Most Recent Earnings -0.08 on 09/30/20
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.415 +12.05%
on 02/25/21
0.650 -28.46%
on 02/16/21
+0.015 (+3.33%)
since 02/02/21
3-Month
0.260 +78.85%
on 12/03/20
0.680 -31.62%
on 12/14/20
+0.195 (+72.22%)
since 12/02/20
52-Week
0.040 +1,062.50%
on 03/17/20
1.150 -59.57%
on 06/08/20
+0.360 (+342.86%)
since 03/02/20

Most Recent Stories

More News
Ketamine Could Potentially Increase Life Expectancy for Lou Gehrig’s Disease Patients

Psychedelics, like ketamine could be a game-changer for the medical community. In addition to psilocybin, ...

MMEDF : 3.5400 (-2.75%)
CMPS : 50.08 (+0.44%)
MYCOF : 0.3720 (+0.51%)
PSYC.CN : 0.485 (-3.00%)
PSYCF : 0.3849 (-2.16%)
PHRRF : 0.2609 (+2.72%)
MYCO.CN : 0.465 (-1.06%)
PHRM.CN : 0.325 (+1.56%)
Medical Breakthroughs Propel Psilocybin Closer to Legalization

, /PRNewswire/ -- The psychedelics market is currently navigating a similar legal situation to the one the cannabis market found itself in for many years. Psychedelics are not legal for recreational use...

NWAV : 0.0088 (+7.32%)
MYCOF : 0.3720 (+0.51%)
MYCO.CN : 0.465 (-1.06%)
AIKI : 1.2400 (-6.77%)
SPOR.CN : 0.125 (-3.85%)
TRMNF : 0.0977 (-11.18%)
PLNT.CN : 0.115 (unch)
VEGGF : 0.0931 (+1.75%)
CODE.CN : 0.510 (-10.53%)
BKLLF : 0.4141 (-4.61%)
Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma company in the life sciences category committed to the research and development, production,...

MYCO.CN : 0.465 (-1.06%)
MYCOF : 0.3720 (+0.51%)
First Movers in the Psychedelics Space Position Themselves as Industry Leaders

, /PRNewswire/ -- The emergence of psychedelics as a mental health solution and as a legitimate industry has been one of the most radical market developments that we have seen in decades. Far from being...

PULL.CN : 0.550 (-5.17%)
PRXTF : 0.4360 (-5.67%)
RVV.CN : 0.470 (-3.09%)
RVVTF : 0.3745 (-3.23%)
MYCO.CN : 0.465 (-1.06%)
MYCOF : 0.3720 (+0.51%)
AIKI : 1.2400 (-6.77%)
CMPS : 50.08 (+0.44%)
Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Partnership Supports Mydecine's Drug Development & Clinical Trials Pipeline

MYCO.CN : 0.465 (-1.06%)
MYCOF : 0.3720 (+0.51%)
Ongoing Public Mental Health Crisis Calls For Innovative Treatments

, /PRNewswire/ -- The ongoing pandemic has inflamed and highlighted a separate but very connected public health crisis that has been growing all around the world for decades. Rates of mental health issues...

PULL.CN : 0.550 (-5.17%)
PRXTF : 0.4360 (-5.67%)
MYCO.CN : 0.465 (-1.06%)
MYCOF : 0.3720 (+0.51%)
RVV.CN : 0.470 (-3.09%)
RVVTF : 0.3745 (-3.23%)
TRYP.CN : 0.910 (-2.15%)
TRYPF : 0.7084 (+0.33%)
JNJ : 159.59 (+0.17%)
Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap's Mental Health Technology

Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company") is pleased to announce that its subsidiary Mindleap Health ("Mindleap"), a digital health platform and...

NLBIF : 0.6150 (-6.82%)
MYCO.CN : 0.465 (-1.06%)
MYCOF : 0.3720 (+0.51%)
Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of...

MYCO.CN : 0.465 (-1.06%)
MYCOF : 0.3720 (+0.51%)
Mydecine Innovations Group Files Final Prospectus in Connection with Bought Deal Offering of Units

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of...

MYCO.CN : 0.465 (-1.06%)
MYCOF : 0.3720 (+0.51%)
Mydecine Innovations Group Files Amended and Restated Financial Statements

Mydecine Innovations Group Inc. (the "Company") (CSE:MYCO | OTC:MYCOF) (FSE: 0NFA) announces it has filed amended and restated unaudited condensed interim consolidated financial statements for the nine-month...

MYCO.CN : 0.465 (-1.06%)
MYCOF : 0.3720 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 0.537
2nd Resistance Point 0.523
1st Resistance Point 0.497
Last Price 0.465
1st Support Level 0.457
2nd Support Level 0.443
3rd Support Level 0.417

See More

52-Week High 1.150
Fibonacci 61.8% 0.726
Fibonacci 50% 0.595
Last Price 0.465
Fibonacci 38.2% 0.464
52-Week Low 0.040

See More

Business Summary

Mydecine Innovations Group Inc is a biopharma and life sciences company. It is committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use. Reinforcing Mydecine's commitment to mental health solutions is underpinned by the company's three main focuses:...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar